Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suzetrigine in Diabetic Peripheral Neuropathy
NCT06696443Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of suzetrigine in diabetic polyneuropathy (DPN), sponsored by Vertex Pharmaceuticals. Started Dec 2024; status: active, not recruiting.
02
Drugs
suzetrigine
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT06696443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696443.